Salmonella infection is an important public health issue for which the needs of antimicrobial treatment are increasing. A total of 546 human clinical S. enterica serovar Typhimurium isolates were recovered from patients in hospitals in China during the period of 2005 to ϳ2011. Twenty percent of the isolates exhibited resistance to ciprofloxacin, and 4% were resistant to ceftriaxone. Importantly, for the first time, 12 (2%) S. Typhimurium isolates resistant to both ciprofloxacin and ceftriaxone were recovered; among these 12 isolates, two were also resistant to azithromycin, and one was resistant to all other drugs tested. The combined effects of various transferrable extended-spectrum ␤-lactamase determinants and a novel efflux-based ciprofloxacin resistance mechanism encoded by the mobile efflux gene oqxAB were responsible for the emergence of these extremely (highly) drug-resistant (XDR) S. Typhimurium isolates. The dissemination of resistance genes, such as those encoding ESBLs and the OqxAB pump, among Salmonella organisms will speed up the selection of XDR Salmonella, posing a huge threat to public health and Salmonella infection control.
F
ood-borne salmonellosis is an important public health problem worldwide and the leading cause of food-borne illnesses in many countries, including the United States and China. Although antimicrobial treatment is not necessary for most cases of salmonellosis, it can be lifesaving in invasive infections (1) . Ceftriaxone and ciprofloxacin are the key drugs of choice for treatment of invasive Salmonella infections (2) . Recently, azithromycin was also approved by the FDA to be an additional agent for treatment of Salmonella infections (3). Resistance to ceftriaxone or other extended-spectrum beta-lactams is usually due to intracellular production of extended-spectrum ␤-lactamases (ESBLs). In Salmonella, the most commonly found ESBL types in Asia are in the CTX-M group (4) , which are usually located on transmissible plasmids that tend to disseminate among members of the Enterobacteriaceae (5) . The most commonly reported CTX-M enzymes in Salmonella strains are CTX-M-9, CTX-M-14, and CTX-M-15 (5) . In other regions, such as the United States and Canada, the AmpC ␤-lactamase CMY-2 is the major contributor to ceftriaxone resistance in Salmonella (6) . On the other hand, ciprofloxacin resistance is mainly attributed to double mutations in gyrA and a single mutation in parC in Salmonella (7) . Efflux pumps and the presence of plasmid-mediated quinolone resistance (PMQR) determinants may also contribute to ciprofloxacin resistance. Qnr genes such as qnrA, qnrB, qnrD, and qnrS have been reported (8, 9) . Recent studies also detected oqxAB, a plasmid-borne gene which encoded an RND efflux pump, in Salmonella isolated from food, animals, and humans (10) (11) (12) . Although resistance to fluoroquinolone or extended-spectrum cephalosporins was increasingly reported in S. enterica serovar Typhimurium, concurrent resistance to ciprofloxacin and ceftriaxone (i.e., extremely drug resistant [XDR] ) has been reported in other serovars, including S. Choleraesuis, S. Kentucky, S. Senftenberg, and S. Oranienburg, but not in S. Typhimurium (13) (14) (15) (16) . This work illustrated the underlying molecular mechanisms responsible for the production of extremely drug-resistant phenotypes in S. Typhimurium.
PMQR genes and target gene mutation screening. The quinolone resistance-determining regions (QRDRs) of gyrA and parC were amplified by PCR as previously described (18) , followed by determination of their nucleotide sequences and comparison to the wild-type Salmonella Typhimurium LT2 strain to identify target gene mutations in the test isolates. The presence of the PMQR genes qnrA, qnrB, qnrC, qnrD, qnrS, qepA, oqxAB, and aac(6=)Ib-cr was determined by PCR using primers described previously and sequencing (18, 19) . The prevalence of ESBLs was determined by PCR targeting known ␤-lactamases as previously described (10) . The full lengths of ␤-lactamase genes were amplified by specific primers for CTX-M group 1 (forward [F], 5=-ATGGTTAAAAAA TCACTGCG; reverse [R], 5= TTACAAACCGTCGGTGAC), CTX-M group 2 (F, 5=-ATGATGACTCAGAGCATTCGC; R, 5=-TCAGAAACCG TGGGTTACGAT), CTX-M group 9 (F, 5=-ATTCAGAGCTCATGGTGA CAAAGAGAGTGC; R, 5=-TAGTAGGATCCTTACAGCCCTTCGGCGA TG), and CMY (F, 5=-ATGATGAAAAAATCGTTATGCT; R, 5=-ATTGC AGCTTTTCAAGAAT), followed by nucleotide sequencing to determine their type specificity.
Conjugation experiments. A conjugative experiment was carried out as previously described (20) using sodium azide-resistant E. coli strain J53 as the recipient. Briefly, overnight cultures of donor and recipient strains were mixed and collected on a filter, which was subjected to overnight incubation on a blood agar plate. The mixture was then spread on double selective blood agar plates containing ceftriaxone (2 g/ml) and sodium azide (100 g/ml) to select drug-resistant transconjugants. Plasmid replicon typing was performed as previously described (21) .
Molecular typing. The clonal relationship between representative Salmonella isolates was examined by pulsed-field gel electrophoresis (PFGE) according to the PulseNet PFGE protocol for Salmonella (22) . S1-PFGE was conducted to determine the size of large plasmids. Briefly, agaroseembedded DNA was digested with S1 nuclease (New England BioLabs) at 37°C for 1 h. The restriction fragments were separated by electrophoresis in 0.5 mM Tris-borate-EDTA buffer at 14°C for 18 h using a CHEF Mapper electrophoresis system (Bio-Rad, Hercules, CA) with pulse times of 2.16 to 63.8 s. A phage Lambda PFGE ladder (New England BioLabs) was used as the DNA size marker. The gels were stained with GelRed, and DNA bands were visualized with UV transillumination (Bio-Rad). Multilocus sequence typing was performed using primer sets as suggested at www.mlst.net.
RESULTS AND DISCUSSION
A total of 546 human clinical S. Typhimurium isolates, accounting for approximately 40% (1,380) of all S. Typhimurium isolates and 9% (5,873) of all Salmonella isolates collected from the State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention (ICDC) of China, during 2005 to ϳ2011 were included in this study. A substantial proportion of these isolates displayed resistance (MIC, Ն4 g/ml) (20%) or intermediate resistance (MIC, 2 g/ml) (16%) to ciprofloxacin. Around 4% of the isolates were resistant to extended-spectrum cephalosporins ( Table 1) . Profiles of resistance to other antimicrobials are shown in Table 1 . All Salmonella isolates were susceptible to meropenem.
The vast majority of 109 (20%) isolates which were resistant to ciprofloxacin also exhibited high-level resistance to other classes of antimicrobials, including sulfamethoxazole (100%), chloramphenicol (97%), ampicillin (94%), tetracycline (94%), kanamycin (92%), trimethoprim (92%), amoxicillin-clavulanic acid (87%), gentamicin (82%), streptomycin (67%), and extended-spectrum cephalosporins (9%) ( Table 1 ). The annual distribution of ciprofloxacin-resistant Salmonella isolates from 2005 to ϳ2011 was 11%, 37%, 20%, 12%, 9%, and 33%, respectively. Among the 22 ceftriaxone-resistant S. Typhimurium isolates, the rates of resistance to different antimicrobials were the following: kanamycin (92%), nalidixic acid (91%), sulfamethoxazole (86%), tetracycline (86%), gentamicin (82%), trimethoprim (72%), streptomycin (64%), and chloramphenicol (59%). Most importantly, 12 of the 22 ceftriaxone-resistant S. Typhimurium isolates also exhibited resistance to ciprofloxacin. Not surprisingly, these isolates exhibited extremely high rates and levels of resistance to all other antimicrobials. Three of them were susceptible to only one antimicrobial (Table 1) . Among these 12 extremely drug-resistant (XDR) S. Typhimurium isolates, two were also resistant to azithromycin; thus, these two isolates were concurrently resistant to ciprofloxacin, ceftriaxone, and azithromycin (Table 1) . Human clinical Salmonella isolates that were resistant to all three of these choices of treatment were only recently reported for S. Kentucky ST198-X1, a much less prevalent serotype (16) . The emergence of S. Typhimurium strains resistant to these three antimicrobials warrants continuous monitoring of the trend of development of antimicrobial resistance in China.
Mechanisms of resistance to ciprofloxacin and ceftriaxone in the 12 XDR S. Typhimurium isolates were investigated. Double gyrA (S83F, D87N) mutations and a single parC (S80R) mutation were detectable in 8 out of 12 XDR S. Typhimurium isolates. The PMQR genes aac(6=)-Ib-cr and qeqA were detected in two isolates (Table 2 ). In contrast to other reports, the remaining 4 isolates harbored only a single gyrA (D87N) mutation. However, oqxAB was detected in all four of these isolates. One of them also con- tained aac(6=)-Ib-cr (Table 2) . A single gyrA mutation, together with oqxAB-mediated efflux, was shown to be a novel mechanism of ciprofloxacin resistance in S. Typhimurium. Further works will be needed to evaluate the relative roles of OqxAB and single-target-gene mutation in the development of fluoroquinolone resistance in S. Typhimurium. Recently, our laboratory confirmed that clonal expansion of an S. Typhimurium ST34 clone carrying multiple resistance determinants, in particular oqxAB and aac(6=)-Ib-cr, occurred in both China and Hong Kong (12) . Therefore, findings of this work further highlight the role of the mobile OqxAB pump in the emergence of XDR phenotypes in Salmonella and the subsequent clonal expansion of such XDR isolates. The ESBL screening and characterization for these S. Typhimurium isolates showed that different variants of the CTX-M family of ␤-lactamases were detectable in XDR S. Typhimurium and that they most likely contributed to the ceftriaxone resistance phenotypes of the host isolates. bla CTX-M-14 was detectable in seven isolates, and bla CTX-M-27 , bla CTX-M-28 , bla CTX-M-79 , bla CTX-M-104 , and bla CMY-2 could be detected in each of the other five S. Typhimurium isolates ( Table 2) Table 2 and showed that four S. Typhimurium clones, ST429, ST588, ST297, and ST277, were able to transfer their ESBL determinants to E. coli J53. The gentamicin resistance determinants of ST588 and ST297 and gentamicin and amikacin resistance determinants of ST429 were also transferrable ( Table 2 ). The resistance determinant for azithromycin was not transferable. S1-PFGE showed that most of the isolates possessed several large-sized plasmids ( Fig. 1 and Table 2 ). Transconjugants of S. Typhimurium harbored plasmids with sizes ranging from 70 kb to 120 kb. IncF-and I1-I␥-type plasmids were the most commonly found replicon types, followed by FIIAs, F1B, HI2, Y, and B/O ( Table 2) . Among the transconjugants, 3 out of 4 harbored an I1-I␥-type plasmid, and the remaining one carried the F1B type. The I1-I␥-type plasmids were found to be dominant among Salmonella strains carrying bla CMY-2 (6). This study reports the detection of different bla CTX-M -containing I1-I␥-type plasmids for the first time and provides evidence that plasmids of this type are disseminating among S. Typhimurium strains in China.
The clonal relationships among the 12 XDR S. Typhimurium isolates were determined. These 12 isolates were found to display unrelated PFGE profiles which were not the dominant PFGE types in China (Fig. 2) . XDR Salmonella isolates were commonly seen in Henan Province in 2007 and 2008 and became common in Shanghai in 2010 and 2011 (Fig. 2) . Nevertheless, multilocus sequence typing showed that 7 of the S. Typhimurium isolates belonged to ST19, a common clone causing human infections worldwide (27) (28) (29) . The remaining 5 isolates belonged to ST34, which is associ- ated with a monophasic variant of S. Typhimurium in Europe with the ASSuTe R-type (27) ( Table 2 and Fig. 2 ).
In conclusion, this study reported the emergence of S. Typhimurium human clinical isolates that were resistant to all classes of antimicrobials tested, including ceftriaxone, ciprofloxacin, and azithromycin, which are common choices of treatment. The selection of these XDR S. Typhimurium isolates may be due to the increasing transmission of different ESBL-encoding elements among ciprofloxacin-resistant S. Typhimurium organisms whose resistance phenotypes are in turn mediated by conventional and novel mechanisms, including a single gyrA mutation and a PMQR gene, oqxAB. Transmission of resistance genes such as those encoding ESBLs and the OqxAB pump in Salmonella will speed up the selection of these XDR Salmonella organisms, which poses a huge threat to human Salmonella infection control. Further works are required to trace the transmission routes of XDR Salmonella strains in clinical settings and develop appropriate intervention strategies.
